Drugs Based on Gene Therapy Market Size, Share, Growth, and Industry Analysis, By Type (By Types (Based on Viral,Based on Non-viral), By Applications (Neurological Diseases,Cancer,Other) ), By Application (AAA), Regional Insights and Forecast to 2035

Drugs Based on Gene Therapy Market Overview

Global Drugs Based on Gene Therapy Market size is projected at USD 9063  million in 2025 and is expected to hit USD 47469.23 million by 2034 with a CAGR of 20.2%.

The Drugs Based on Gene Therapy Market is rapidly expanding as biotechnology innovation accelerates the development of advanced therapeutic drugs targeting genetic disorders. Gene therapy drugs modify or replace defective genes to treat inherited diseases, cancers, and rare disorders. The global Drugs Based on Gene Therapy Market Report indicates strong adoption driven by clinical pipeline expansion, regulatory approvals, and precision medicine strategies. More than 4,000 gene therapy clinical trials are currently active worldwide, targeting over 250 rare diseases. Viral vectors represent nearly 65% of gene delivery technologies used in approved therapies. 

The United States dominates the Drugs Based on Gene Therapy Market due to strong biotechnology infrastructure, advanced clinical research facilities, and extensive regulatory frameworks. The U.S. hosts more than 55% of global gene therapy clinical trials, with over 2,200 active trials targeting genetic disorders, oncology, and neurological diseases. The country has approved over 10 gene therapy drugs through regulatory agencies and continues expanding manufacturing facilities for viral vector production. Approximately 70% of biotechnology funding in North America supports genetic medicine development. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 62% increase in genetic disease diagnosis rates, 48% expansion in biotechnology R&D investments, 55% growth in clinical trials focused on gene therapy drugs, 37% improvement in gene editing efficiency, and 41% rise in regulatory approvals for advanced therapy medicinal products.
• Major Market Restraint: Nearly 46% of therapy programs face manufacturing complexity challenges, 39% higher treatment costs impact adoption, 34% regulatory compliance barriers in multiple countries, 29% limitations in viral vector production capacity, and 31% concerns regarding long-term therapy safety.
• Emerging Trends: Approximately 52% increase in CRISPR-based therapy development, 44% adoption of non-viral gene delivery systems, 36% expansion in personalized genomic medicine programs, 42% rise in AI-assisted drug discovery platforms, and 47% integration of precision diagnostics in treatment protocols.
• Regional Leadership: North America accounts for nearly 49% of global gene therapy clinical programs, Europe contributes around 27% of advanced therapy research projects, Asia-Pacific supports 18% of biotechnology manufacturing capacity, and emerging markets represent approximately 6% of gene therapy adoption initiatives.
• Competitive Landscape: Around 58% of market innovation originates from biotechnology startups, 33% from pharmaceutical companies, 46% of partnerships involve academic institutions, 40% of companies focus on viral vector platforms, and 35% emphasize genome editing technologies.
• Market Segmentation: Viral vector therapies represent nearly 65% of delivery systems, non-viral platforms account for 35%, oncology applications cover about 38% of therapy programs, rare genetic diseases contribute 33%, neurological disorders represent 17%, and metabolic diseases contribute around 12%.
• Recent Development: Approximately 43% increase in gene therapy regulatory submissions, 39% growth in vector manufacturing facilities, 41% expansion in rare disease therapy pipelines, 36% increase in biotechnology mergers and collaborations, and 32% improvement in gene therapy treatment success rates.

Drugs Based on Gene Therapy Market Latest Trends

The Drugs Based on Gene Therapy Market Trends show rapid transformation driven by precision medicine and genomic research. Pharmaceutical companies are significantly expanding gene therapy pipelines targeting rare genetic disorders such as hemophilia, spinal muscular atrophy, and inherited retinal diseases. Over 4,000 global clinical trials are currently investigating gene-based treatments, with approximately 38% focused on oncology indications. Viral vector technology dominates therapeutic delivery platforms, particularly adeno-associated virus vectors which account for nearly 60% of ongoing clinical programs. 

Another important development highlighted in the Drugs Based on Gene Therapy Market Research Report is the rapid growth of advanced therapy manufacturing facilities. More than 120 specialized viral vector production sites have been established globally to meet increasing clinical demand.. Additionally, over 250 rare diseases currently under investigation are expected to benefit from gene-based therapeutic drugs. Strategic partnerships between biotechnology companies, research institutes, and pharmaceutical manufacturers have increased by nearly 40%, accelerating innovation and expanding the Drugs Based on Gene Therapy Market Opportunities for next-generation genetic medicines.

Drugs Based on Gene Therapy Market Dynamics

DRIVER

"Rising Demand for Genetic Disease Treatments"

The primary growth driver in the Drugs Based on Gene Therapy Market Growth is the increasing prevalence of inherited genetic disorders worldwide. More than 300 million individuals globally are affected by rare diseases, with nearly 80% linked to genetic mutations. Gene therapy drugs offer long-term therapeutic benefits by targeting underlying genetic defects rather than treating symptoms. Healthcare institutions report over 250 rare diseases currently being investigated through gene therapy research programs. Additionally, around 38% of gene therapy clinical trials focus on oncology treatments, demonstrating strong expansion into cancer therapy applications. 

RESTRAINTS

"High Development and Manufacturing Complexity"

Despite strong innovation, the Drugs Based on Gene Therapy Market faces challenges related to manufacturing complexity and treatment costs. Gene therapy drug development requires advanced laboratory infrastructure, viral vector manufacturing capabilities, and specialized regulatory approval processes. Manufacturing gene therapy drugs involves complex cell engineering and viral vector production, which increases operational costs significantly. Approximately 29% of therapy developers report limitations in viral vector supply, affecting clinical trial timelines. Regulatory compliance across multiple regions further complicates commercialization strategies. 

OPPORTUNITY

"Expansion of Personalized Medicine Technologies"

The Drugs Based on Gene Therapy Market Opportunities are expanding with the rapid advancement of personalized medicine and genomic diagnostics. Precision medicine programs now utilize genetic sequencing technologies to identify disease-causing mutations and develop customized therapeutic drugs. More than 1,500 hospitals worldwide have integrated genomic testing platforms for personalized treatment planning. The global genomic sequencing capacity has increased by nearly 50% in the past decade, enabling faster identification of gene targets for therapy development. Pharmaceutical companies are collaborating with genomic research institutions to develop individualized gene therapies tailored to specific patient genetic profiles, strengthening the overall Drugs Based on Gene Therapy Market Outlook.

CHALLENGE

"Regulatory and Long-Term Safety Concerns"

Regulatory oversight and long-term therapy monitoring remain major challenges affecting the Drugs Based on Gene Therapy Market Insights. Gene therapy drugs require extensive clinical evaluation to ensure long-term safety and therapeutic durability. Regulatory agencies demand comprehensive multi-year follow-up studies for patients receiving gene therapy treatments. Approximately 35% of clinical programs require extended safety monitoring due to concerns regarding immune responses or unintended genetic modifications. Ethical considerations surrounding genetic modification technologies also influence regulatory approvals in certain countries. 

Drugs Based on Gene Therapy Market Segmentation

The Drugs Based on Gene Therapy Market segmentation highlights the classification of gene therapy drugs by delivery technology and clinical application. Delivery platforms include viral and non-viral gene transfer systems that enable targeted modification of defective genes. Viral vectors represent a dominant proportion of gene therapy development pipelines due to their high transduction efficiency, while non-viral technologies are expanding due to improved safety profiles. Application segmentation covers neurological diseases, cancer, and other genetic disorders. 

Download Free Sample to learn more about this report.

BY TYPE

Based on Viral: Viral vector-based therapies represent the most widely adopted delivery method within the Drugs Based on Gene Therapy Market due to their high efficiency in transferring genetic material into human cells. Viral vectors are engineered viruses designed to deliver therapeutic DNA without causing disease. Adeno-associated virus (AAV), lentivirus, retrovirus, and adenovirus platforms dominate the viral vector ecosystem used in gene therapy drugs. AAV vectors alone account for nearly 60% of ongoing gene therapy clinical trials because they offer strong safety profiles and long-term gene expression capabilities. Lentiviral vectors represent approximately 20% of therapeutic development programs and are frequently used in treatments targeting hematological conditions and immune system disorders. More than 2,400 global clinical trials utilize viral vectors for gene therapy drug development, targeting over 200 genetic disorders. Viral-based therapies have shown significant success in treating inherited retinal disorders, hemophilia, spinal muscular atrophy, and certain rare metabolic diseases. 

Based on Non-viral: Non-viral gene therapy delivery technologies represent an emerging and rapidly expanding segment within the Drugs Based on Gene Therapy Market. These systems deliver therapeutic genetic material without using viral carriers, reducing potential immune responses and simplifying manufacturing processes. Non-viral platforms include lipid nanoparticles, polymer-based vectors, electroporation techniques, and plasmid DNA delivery systems. Lipid nanoparticle delivery systems have gained considerable attention due to their success in RNA-based therapies and genetic medicine platforms. Nearly 35% of gene therapy development programs now incorporate non-viral delivery technologies to improve treatment safety and scalability. Non-viral gene transfer methods are particularly attractive for repeated dosing strategies. Unlike viral vectors, non-viral platforms can be administered multiple times without triggering strong immune reactions. 

BY APPLICATION

Neurological Diseases: Gene therapy drugs targeting neurological diseases represent a rapidly expanding segment in the Drugs Based on Gene Therapy Market due to the increasing prevalence of inherited and degenerative neurological disorders. Conditions such as spinal muscular atrophy, Huntington’s disease, Parkinson’s disease, and inherited retinal degeneration are major focus areas for gene therapy research. More than 300 million individuals worldwide are affected by neurological disorders, and many of these conditions are linked to genetic mutations that can potentially be corrected through gene therapy interventions. Approximately 18% of global gene therapy clinical trials currently focus on neurological disorders. Among these programs, spinal muscular atrophy remains one of the most widely studied diseases due to its clear genetic cause involving mutations in the SMN1 gene. Gene therapy approaches aim to replace defective genes or introduce functional copies into affected neurons, restoring normal protein production. In inherited retinal diseases, gene therapy drugs target mutations affecting photoreceptor cells, which are responsible for vision impairment and progressive blindness. 

Cancer: Oncology represents one of the most significant application segments in the Drugs Based on Gene Therapy Market due to the growing use of genetic medicine to treat complex cancers. Gene therapy drugs are designed to modify cancer cells, activate immune responses, or introduce genes that destroy tumor cells. Nearly 38% of global gene therapy clinical trials target oncology applications, making cancer the largest therapeutic category within genetic medicine research. Gene therapy strategies used in cancer treatment include tumor suppressor gene replacement, suicide gene therapy, immune cell modification, and oncolytic virus therapies. Oncolytic viruses are engineered to selectively infect and destroy cancer cells while stimulating immune responses against tumors. More than 80 clinical trials currently investigate oncolytic viral therapies for cancers such as melanoma, glioblastoma, and pancreatic tumors. Another important approach involves genetically engineered immune cells designed to recognize and attack cancer cells. CAR-T cell therapies represent a key innovation within gene therapy oncology applications.

Other: The “other” application category within the Drugs Based on Gene Therapy Market includes treatments targeting rare genetic disorders, metabolic diseases, cardiovascular conditions, and immune system deficiencies. Rare diseases represent a particularly significant focus area because nearly 80% of these conditions are linked to genetic mutations that can potentially be corrected through gene therapy drugs. Globally, more than 7,000 rare diseases have been identified, affecting approximately 300 million individuals. Gene therapy programs targeting metabolic disorders have demonstrated promising outcomes. Diseases such as hemophilia, beta-thalassemia, and lysosomal storage disorders are being investigated through gene replacement therapies that restore functional gene expression in affected cells. Hemophilia alone affects more than 400,000 individuals worldwide, and gene therapy drugs aim to introduce genes responsible for producing clotting factors in the liver. Immune deficiency disorders also represent a major research focus. 

Drugs Based on Gene Therapy Market Regional Outlook

The regional distribution of the Drugs Based on Gene Therapy Market demonstrates strong concentration in developed biotechnology ecosystems supported by advanced clinical infrastructure, research institutions, and regulatory frameworks. North America holds approximately 49% of the global Drugs Based on Gene Therapy Market share due to extensive biotechnology innovation and the highest number of active clinical trials. Europe contributes around 27% market share supported by government-backed genomic medicine initiatives and large-scale clinical research programs. Asia-Pacific represents nearly 18% of the global market as countries expand biotechnology manufacturing capabilities and increase genomic research investments. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America represents the largest regional segment of the Drugs Based on Gene Therapy Market, accounting for nearly 49% of global market share due to strong biotechnology innovation, advanced research facilities, and extensive clinical trial activity. The region has the highest concentration of biotechnology companies developing gene therapy drugs and the largest number of regulatory-approved genetic therapies. The United States dominates the regional landscape, contributing more than 85% of North America’s gene therapy research programs. Over 2,200 gene therapy clinical trials are currently active across North America, targeting rare genetic disorders, cancers, and neurological diseases. The region has over 300 biotechnology companies actively involved in gene therapy development, many of which focus on viral vector technologies and gene editing platforms. Approximately 60% of clinical programs in North America utilize adeno-associated viral vectors due to their efficiency in delivering therapeutic genes. Manufacturing infrastructure also plays a critical role in the regional market. More than 70 specialized viral vector production facilities operate across North America, supporting clinical trial supply chains and commercial gene therapy drug production.

EUROPE

Europe holds approximately 27% share of the global Drugs Based on Gene Therapy Market, driven by strong regulatory frameworks, public research funding, and collaborative biotechnology innovation across multiple countries. The region hosts more than 900 gene therapy clinical trials targeting rare diseases, oncology conditions, and neurological disorders. European governments have established several genomic medicine initiatives aimed at accelerating genetic disease diagnosis and improving patient access to advanced therapies. The European biotechnology sector includes more than 200 companies engaged in gene therapy drug development. Viral vector technologies dominate the regional pipeline, accounting for nearly 55% of gene delivery platforms used in clinical trials. Lentiviral vectors are widely used in European research programs, particularly for treatments targeting blood disorders and immune system deficiencies. Research collaborations between universities, pharmaceutical companies, and biotechnology startups continue to expand the gene therapy innovation ecosystem throughout the region. 

GERMANY Drugs Based on Gene Therapy Market

Germany represents one of the leading biotechnology hubs in Europe and contributes approximately 21% of the regional Drugs Based on Gene Therapy Market share. The country has developed a strong genetic medicine research ecosystem supported by advanced academic institutions, pharmaceutical manufacturers, and biotechnology startups. Germany hosts more than 120 biotechnology companies focused on genetic medicine, many of which are actively involved in gene therapy drug discovery and development. The German healthcare research infrastructure includes numerous genomic medicine laboratories and specialized biotechnology research centers. More than 150 gene therapy research projects are currently active in Germany, targeting rare genetic diseases, neurological disorders, and cancer. Universities and research institutes collaborate with biotechnology companies to accelerate the translation of genetic discoveries into therapeutic drugs. Germany’s clinical research environment also supports gene therapy innovation. Over 200 clinical trials involving gene therapy drugs are currently conducted within the country. 

UNITED KINGDOM Drugs Based on Gene Therapy Market

The United Kingdom holds approximately 19% share of the European Drugs Based on Gene Therapy Market and has established itself as a leading center for genomic medicine and biotechnology innovation. The country hosts more than 100 biotechnology companies involved in gene therapy drug development, along with several globally recognized genomic research institutions. The United Kingdom has conducted more than 180 gene therapy clinical trials targeting genetic disorders and cancer treatments. Many of these trials focus on advanced gene editing technologies and immune cell therapies designed to treat complex diseases. Oncology programs represent nearly 35% of gene therapy clinical studies conducted within the country. Genomic sequencing programs have played a critical role in strengthening the United Kingdom’s gene therapy research ecosystem. National genomic initiatives have sequenced hundreds of thousands of human genomes, enabling researchers to identify disease-causing genetic mutations and develop targeted gene therapies. 

ASIA-PACIFIC

Asia-Pacific accounts for approximately 18% of the global Drugs Based on Gene Therapy Market share and represents one of the fastest expanding regions in genetic medicine research. Countries such as China, Japan, South Korea, and India are increasing investments in biotechnology infrastructure, genomic research, and advanced therapy manufacturing facilities. More than 500 gene therapy clinical trials are currently active across Asia-Pacific, focusing on oncology treatments, rare genetic disorders, and neurological diseases. China and Japan together represent nearly 70% of the region’s gene therapy research programs. Governments across the region are introducing policies aimed at accelerating biotechnology innovation and supporting clinical trial development. Asia-Pacific has also significantly expanded its biotechnology manufacturing capabilities. More than 40 vector production facilities have been established across the region to support gene therapy research and drug production. 

JAPAN Drugs Based on Gene Therapy Market

Japan represents approximately 28% of the Asia-Pacific Drugs Based on Gene Therapy Market share and is recognized for its advanced biotechnology research environment. The country has invested heavily in regenerative medicine and genetic therapy innovation through government-backed research initiatives and academic collaborations. Japan currently hosts more than 120 gene therapy clinical trials focusing on neurological disorders, cancer, and rare genetic diseases. The country’s regulatory framework supports accelerated approval pathways for advanced therapies, encouraging biotechnology companies to develop innovative genetic treatments. Academic research institutions in Japan contribute significantly to gene therapy innovation. Universities and research centers are actively studying viral vector engineering, gene editing technologies, and genomic diagnostics. 

CHINA Drugs Based on Gene Therapy Market

China accounts for approximately 35% of the Asia-Pacific Drugs Based on Gene Therapy Market share and represents one of the most rapidly expanding biotechnology ecosystems in the world. The country has significantly increased investments in genomic research, biotechnology infrastructure, and gene therapy drug development. China currently hosts more than 300 active gene therapy clinical trials, making it one of the largest centers for genetic medicine research globally. Many of these trials focus on cancer treatments, which represent nearly 40% of the country’s gene therapy research programs. Oncolytic virus therapies and genetically modified immune cell treatments are major areas of development within Chinese biotechnology laboratories. The Chinese government has introduced several national biotechnology innovation programs aimed at accelerating gene therapy research. 

MIDDLE EAST & AFRICA

The Middle East and Africa region holds approximately 6% share of the global Drugs Based on Gene Therapy Market and represents an emerging landscape for genetic medicine research and clinical development. Although the region currently has fewer biotechnology companies compared with North America and Europe, several countries are investing in genomic research infrastructure and rare disease diagnosis programs. More than 60 gene therapy research projects are currently active across the Middle East and Africa, focusing primarily on inherited genetic disorders and metabolic diseases. Countries such as the United Arab Emirates, Saudi Arabia, and South Africa are leading biotechnology research initiatives within the region. Genomic medicine programs are expanding across the Middle East, where genetic disorders are more prevalent due to higher rates of inherited conditions. National genome sequencing projects have been launched to identify disease-causing genetic mutations and improve early diagnosis of rare diseases. 

List of Key Drugs Based on Gene Therapy Market Companies

• Biogen
• Novartis
• Gilead Sciences
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• Amgen
• Spark Therapeutics
• Akcea Therapeutics
• Bluebird bio
• Sunway Biotech
• SIBIONO
• AnGes
• Orchard Therapeutics
• Human Stem Cells Institute

Top Two Companies with Highest Share

• Novartis: approximately 14% global share driven by multiple approved gene therapy products and involvement in nearly 9% of global gene therapy clinical programs.
• Gilead Sciences: around 11% global share supported by strong cell and gene therapy development pipelines representing nearly 8% of ongoing genetic therapy trials.

Investment Analysis and Opportunities

The Drugs Based on Gene Therapy Market continues to attract significant investment activity due to increasing demand for advanced genetic treatments and rising rare disease diagnosis rates. Approximately 48% of biotechnology venture capital funding currently targets gene therapy platforms, reflecting strong investor confidence in genomic medicine technologies. Nearly 36% of pharmaceutical companies have expanded their investment portfolios to include gene editing platforms, viral vector manufacturing infrastructure, and genomic sequencing research. Global biotechnology collaborations related to gene therapy research have increased by nearly 41%, enabling companies to accelerate the development of targeted therapeutic drugs. Academic institutions contribute to roughly 34% of early-stage gene therapy innovations, creating additional partnership opportunities for biotechnology investors seeking to commercialize emerging therapies.

Investment opportunities are also expanding within manufacturing infrastructure for gene therapy drugs. Nearly 39% of biotechnology manufacturers are increasing capacity for viral vector production to address growing clinical trial demand. Approximately 44% of investment initiatives focus on developing next-generation delivery platforms such as lipid nanoparticles and synthetic gene carriers. Governments and public research organizations support about 32% of genetic medicine funding programs, encouraging innovation in rare disease treatment. Precision medicine technologies are another major investment focus, with about 37% of healthcare technology companies investing in genomic diagnostics that support gene therapy drug development. As personalized medicine adoption increases globally, investors are directing approximately 42% of biotechnology funding toward gene therapy companies with strong clinical pipelines and scalable manufacturing technologies.

New Products Development

New product development within the Drugs Based on Gene Therapy Market is accelerating as biotechnology companies expand clinical pipelines targeting genetic disorders and cancer treatments. Approximately 38% of gene therapy drug development programs focus on oncology applications, where genetic modification techniques are used to activate immune responses against tumor cells. Viral vector technologies remain the most widely used delivery systems, accounting for nearly 60% of gene therapy drugs currently under clinical investigation. Researchers are also developing advanced gene editing platforms that allow precise correction of genetic mutations responsible for inherited diseases. Nearly 27% of new product development programs incorporate CRISPR-based technologies to improve treatment precision and therapeutic outcomes.

Another significant trend in product development involves the creation of next-generation delivery systems designed to improve gene targeting efficiency. Approximately 35% of biotechnology companies are developing non-viral gene therapy platforms that reduce immune reactions and allow repeated therapeutic dosing. Lipid nanoparticle technologies have gained particular attention, representing around 24% of emerging gene therapy delivery systems. Additionally, about 31% of new gene therapy drugs are designed specifically for rare diseases, reflecting the high prevalence of inherited disorders worldwide. Pharmaceutical companies are increasingly collaborating with genomic research laboratories, with nearly 40% of new therapy programs developed through joint research partnerships focused on personalized genetic medicine.

Five Recent Developments

• Novartis: In 2024, the company expanded its gene therapy research programs by increasing its clinical trial portfolio by nearly 18%, focusing on rare neurological diseases and inherited metabolic disorders. Approximately 22% of its biotechnology research workforce is currently dedicated to gene therapy innovation.
• Gilead Sciences: In 2024, the company strengthened its cell and gene therapy manufacturing infrastructure by expanding viral vector production capacity by nearly 25%, enabling support for additional clinical trials targeting oncology and genetic immune disorders.
• Sarepta Therapeutics: In 2024, the company increased its gene therapy development programs targeting muscular disorders, expanding its clinical research pipeline by about 19% and advancing multiple therapies designed to restore dystrophin production in muscle cells.
• Bluebird bio: In 2024, the company advanced gene therapy research targeting blood disorders, with approximately 16% expansion in clinical trial enrollment focused on beta-thalassemia and sickle cell disease genetic treatments.
• Spark Therapeutics: In 2024, the company expanded research programs targeting inherited retinal diseases, increasing its genetic medicine research projects by nearly 14% while strengthening collaborations with academic research laboratories.

Report Coverage Of Drugs Based on Gene Therapy Market

The Drugs Based on Gene Therapy Market Report Coverage provides a comprehensive evaluation of global market dynamics, technological advancements, competitive landscape, and regional performance across the genetic medicine industry. The report analyzes key market segments including viral vector and non-viral gene delivery platforms along with major therapeutic applications such as cancer, neurological disorders, and rare genetic diseases. Approximately 65% of the analysis focuses on viral vector technologies due to their dominant role in gene therapy drug development, while nearly 35% of research coverage highlights emerging non-viral delivery innovations. The report also evaluates more than 4,000 ongoing gene therapy clinical trials and analyzes therapeutic pipelines targeting over 250 rare diseases.

The market research report further provides insights into regional biotechnology ecosystems, including North America with approximately 49% market share, Europe representing around 27%, Asia-Pacific contributing nearly 18%, and Middle East and Africa accounting for about 6% of the global market landscape. Competitive analysis covers more than 100 biotechnology companies engaged in gene therapy drug development, with approximately 58% of innovation driven by biotechnology startups and about 33% led by established pharmaceutical companies. The report also examines investment trends, research collaborations, and advanced manufacturing technologies that influence gene therapy commercialization. Strategic analysis of clinical pipeline growth, genomic medicine programs, and precision medicine adoption further supports comprehensive understanding of the Drugs Based on Gene Therapy Market Insights and future growth opportunities within the global genetic medicine industry.